[{"address1": "7171 Rue Frederick Banting", "city": "Saint-Laurent", "state": "QC", "zip": "H4S 1Z9", "country": "Canada", "phone": "514 332 4888", "website": "https://www.engene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Gu\u00e9rin. The company was founded in 2023 and is based in Saint-Laurent, Canada.", "fullTimeEmployees": 31, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jason D. Hanson Esq., J.D.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 656577, "exercisedValue": 0, "unexercisedValue": 23588352}, {"maxAge": 1, "name": "Dr. Alex  Nichols Ph.D.", "age": 37, "title": "President & COO", "yearBorn": 1986, "fiscalYear": 2023, "totalPay": 504442, "exercisedValue": 0, "unexercisedValue": 3900970}, {"maxAge": 1, "name": "Dr. James C. Sullivan M.Sc., Ph.D.", "age": 44, "title": "Chief Scientific Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 524286, "exercisedValue": 0, "unexercisedValue": 2561114}, {"maxAge": 1, "name": "Dr. Anthony T. Cheung Ph.D.", "age": 51, "title": "Co-Founder & CTO", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 341754, "exercisedValue": 0, "unexercisedValue": 13448566}, {"maxAge": 1, "name": "Mr. John C. Brown D.Sc., FRSC, Ph.D.", "title": "Co-Founder and Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David Ryan Daws", "age": 49, "title": "CFO & Head of Business Development", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lee G. Giguere", "age": 42, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sharon  Tan", "title": "VP of Project Management & Head of Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard P. Bryce MBChB, MFPM, MRCGP", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raj  Pruthi M.D.", "title": "Senior VP of Urologic Oncology & Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.97, "open": 8.98, "dayLow": 8.5423, "dayHigh": 9.7, "regularMarketPreviousClose": 8.97, "regularMarketOpen": 8.98, "regularMarketDayLow": 8.5423, "regularMarketDayHigh": 9.7, "beta": -0.641, "forwardPE": -5.968354, "volume": 55528, "regularMarketVolume": 55528, "averageVolume": 86258, "averageVolume10days": 113840, "averageDailyVolume10Day": 113840, "marketCap": 416487264, "fiftyTwoWeekLow": 6.69, "fiftyTwoWeekHigh": 47.17, "fiftyDayAverage": 11.95748, "twoHundredDayAverage": 11.759015, "currency": "USD", "enterpriseValue": 176360880, "floatShares": 14849988, "sharesOutstanding": 44166200, "sharesShort": 17349, "sharesShortPriorMonth": 19755, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.13344, "heldPercentInstitutions": 0.8201, "shortRatio": 0.18, "shortPercentOfFloat": 0.0005, "impliedSharesOutstanding": 44166200, "bookValue": 5.502, "priceToBook": 1.7139223, "lastFiscalYearEnd": 1698710400, "nextFiscalYearEnd": 1730332800, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -115345000, "trailingEps": -2.61, "forwardEps": -1.58, "enterpriseToEbitda": -3.961, "52WeekChange": -0.12115562, "SandP52WeekChange": 0.22553468, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ENGN", "underlyingSymbol": "ENGN", "shortName": "enGene Holdings Inc.", "longName": "enGene Holdings Inc.", "firstTradeDateEpochUtc": 1643725800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f9f4e2ed-4011-3f93-916a-f8a188a8b358", "messageBoardId": "finmb_9516520", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.43, "targetHighPrice": 40.0, "targetLowPrice": 27.0, "targetMeanPrice": 33.0, "targetMedianPrice": 34.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 264810000, "totalCashPerShare": 5.996, "ebitda": -44523000, "totalDebt": 24684000, "quickRatio": 42.233, "currentRatio": 42.802, "debtToEquity": 10.159, "operatingCashflow": -35608000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]